Our company’s name is derived from the Greek word, Entelia, meaning a situation of excellence; without fault, having all the required elements, qualities or characteristics.
Developing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Conventional medicines treat the symptoms instead of the genetic cause of severe and life-threatening diseases, meaning that patients must take these therapies throughout their lives.
Intellia is revolutionizing medicine by harnessing the power of genome editing to develop potential cures. We bring new hope for people living with conditions including cancer, genetic disorders, viral infections, inflammatory disorders and many more.
- Unleashing the power of genome editing to transform medicine by correcting the underlying genetic cause of disease
- Developing genome editing solutions for personalized and curative treatments
- Broadening the potential application with a simplified manufacturing process
- Harnessing DNA’s natural pathways to safely and effectively treat, and even cure, patients
Intellia is at the center of a scientific revolution – in a unique position to use its unmatched, powerful and precise technology to correct the genetic causes of disease.
Intellia can unlock the promise of genome editing using CRISPR/Cas9 to create a new class of therapeutic products.
Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.
We believe we are well positioned to maximize the potential of the CRISPR/Cas9 system to develop therapeutics by maintaining:
- A strong product focus
- Deep management expertise
- Effective product-centric partnerships
- A multi-pronged discovery approach to allow concurrent product in and across multiple organs
- A risk-mitigated approach across platforms to ensure speed of development
- Delivery expertise
- Leading intellectual property position
We are extending this foundational platform, and broadening and optimizing our pipeline, through strategic engagements with partners in industry and academia.
- With a strong, diversified pipeline of experimental therapies, as well as our scientific and clinical development expertise, we can accelerate the path to the clinic and drive rapid expansion
- Proprietary lipid nanoparticle delivery technology provides an innovative platform for safe and effective treatments
- Partnering with leading companies and academic institutions expands our capabilities and further enables significant growth opportunities